Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Staphylococcus aureus infections during peritoneal dialysis

G A Coles1

  • 1Institute of Nephrology, Cardiff Royal Infirmary, Wales, UK.

Journal of Chemotherapy (Florence, Italy)
|July 1, 1995
PubMed
Summary

Peritoneal dialysis patients face infection risks, particularly exit-site infections (ESIs) caused by Staphylococcus aureus. Nasal mupirocin prophylaxis shows promise in reducing S. aureus ESIs, though cost-effectiveness is under evaluation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Confirmation of a gene locus for medullary cystic kidney disease (MCKD2) on chromosome 16p12.

Kidney international·2001
Same author

Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels.

Kidney international·2001
Same author

Clinical research in peritoneal dialysis.

Contributions to nephrology·2000
Same author

Long-term peritoneal membrane changes.

Advances in renal replacement therapy·2000
Same author

In vivo exposure to bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2000
Same author

Biocompatibility and new fluids.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·1999

Area of Science:

  • Nephrology
  • Infectious Diseases
  • Medical Microbiology

Background:

  • Peritoneal dialysis is a common treatment for chronic renal failure.
  • Infections, including peritonitis and exit-site infections (ESIs), are significant complications.
  • Staphylococcus aureus is a primary cause of ESIs, with nasal carriage increasing risk.

Purpose of the Study:

  • To evaluate the efficacy of nasal mupirocin in reducing Staphylococcus aureus-induced exit-site infections in peritoneal dialysis patients.
  • To assess the impact of exit-site care on infection rates.

Main Methods:

  • A large, multicenter, double-blind trial was conducted.
  • Participants received either nasal mupirocin or a placebo for prophylaxis.
  • Infection rates, specifically ESIs, were monitored.

Main Results:

  • Preliminary results indicate a reduction in the incidence of S. aureus-induced ESIs with nasal mupirocin prophylaxis.
  • The study evaluated the influence of exit-site care on infection rates.

Conclusions:

  • Nasal mupirocin prophylaxis appears effective in decreasing Staphylococcus aureus exit-site infections in peritoneal dialysis patients.
  • Further evaluation of cost benefits for this prophylactic regimen is ongoing.

Related Experiment Videos